Combining CRISPR and transposon-based technologies for improved sdAb-based CAR-T therapies

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Combining CRISPR and transposon-based technologies for improved sdAb-based CAR-T therapies

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Discover the potential of transposon and genome editing technologies to develop next-generation, cost-effective single-domain antibody (sdAb) CAR-T therapies. This webinar will explore how non-viral delivery of CAR constructs using a transposon system enhances manufacturing efficiency, improves cell viability through optimized electroporation methods, and enables the creation of universal allogenic CAR-T cells. Attendees will gain insight into how combining genome editing tools such as CRIPSR/Cas9 and base editing with transposon systems supports the rapid, scalable production of therapeutic-grade CAR-T cells.

The speakers will demonstrate key pre-clinical findings showcasing the comparable in vitro and in vivo antitumor efficacy of transposon-based CAR-T cells relative to conventional CAR-T therapies. They will highlight the development of robust, GMP-compliant manufacturing protocols that have previously supported the initiation of clinical trials for patients with relapsed or refractory lymphoma. Lastly, they will delve into how a streamlined, one-step process for the generation of universal CAR-T cells can reduce costs and accelerate clinical translation, while maintaining potency and durability in hematological malignancy models.

Attend this webinar to:

Understand how non-viral transposon systems can improve the efficiency and scalability of CAR-T manufacturing
Learn how to integrate CRISPR/Cas9 and base editing technologies with transposon-based methods to create universal allogeneic CAR-T cells
Gain insights into pre-clinical evidence demonstrating that transposon-based and universal CAR-T cells achieve comparable efficacy to conventional CAR-T cells in vivo and in vitro
Explore robust GMP-compliant manufacturing strategies that enable cost-effective clinical translation of viral-free CAR-T therapies

Begoña Diez Cabezas

Researcher CIEMAT/CIBERER/IIS-FJDager at CliniStem (GMP facility)

In 2015, Begoña Díez Cabezas obtained the doctorate in Genetics and Cell Biology from the Universidad Autómona from Madrid with the qualification of outstanding Cum Laude and the European doctorate mention. In 2016, she moved to London, United Kingdom, where she did her first post-doctoral degree at the UCL GOS ICH, focused on the development of a gene therapy approach based on T lymphocytes for the treatment of a primary immunodeficiency, led by Dr Claire Booth. Since October 2017, she has continued her work as a post-doctoral scientist in the Biomedical Innovation department at CIEMAT, focused on the production of different gene and cell therapy drugs in the GMP Clinistem facility, first as a production supervisor and since 2022 as a production manager. She has also been collaborating in the development of new CAR-T therapies for the treatment of different neoplasms.

Juan Roberto Rodriguez-Madoz

Investigator Immune Therapies Lab. Hematology Oncology-Program, Cima Universidad de Navarra

Juan R. Rodriguez-Madoz obtained his PhD degree in Biology in 2005 at the University of Navarra. His doctoral studies were focused on the development of novel gene therapy approaches for liver cancer. In 2007, he joined the Microbiology Department of the Mount Sinai School of Medicine in New York (USA) as a postdoctoral researcher. After his postdoctoral studies, he joined the Hemato-Oncology Program at the Cima Universidad de Navarra, where he is principal investigator of the Immune Therapies Laboratory. His research line is focused on the development of improved CAR T therapies for hematological malignancies by combining state-of-the-art genome editing and non-viral technologies. His laboratory is also focused on the understanding of molecular mechanisms governing CAR-T cell function, combining multiomic approaches at the single-cell level with spatial transcriptomics.